RESEARCH / PARTICIPATIONBack to the library
← Find a study
Recruiting · registry status

Ambroxol for Parkinson's linked to the GBA1 gene

Researchers are investigating whether ambroxol changes the course of Parkinson's in people with a particular genetic change.

Testing a treatment or activity · Study reference: NCT05830396

Plain-language introduction written with AI from the registry; not independently checked by a clinician. Read the original details below ↓

This registry record was last updated over six months ago, or its update date is missing. Recruitment may have changed. Confirm with the team before making plans.

Open the official registry record ↗

Follow this study

Looking for volunteers

Start (planned)
2023-01-02
Study finished (planned)
2025-07-01

Planned dates can move. A study finishing does not tell us when a paper will be published.

No results summary has been confirmed in the registry records we imported. See connected papers below; we keep checking after recruitment ends.

Changes we have recorded
  • 2026-10-11 — recruiting

These are dates we observed a change, not necessarily the dates it happened.

Papers connected to this study

Study protocol of the GRoningen early-PD Ambroxol treatment (GREAT) trial: a randomized, double-blind, placebo-controlled, single center trial with ambroxol in Parkinson patients with a GBA mutation
This paper mentions the study ID; the relationship needs review · 2024

Moes HR, Buskens E, van Laar T. Continuous subcutaneous levodopa-carbidopa infusion for Parkinson's disease. Lancet Neurol. 2024 Sep;23(9):856-857. doi: 10.1016/S1474-4422(24)00272-2. No abstract available. ↗
Registry derived research reference

Siemeling O, Slingerland S, van der Zee S, van Laar T. Study protocol of the GRoningen early-PD Ambroxol treatment (GREAT) trial: a randomized, double-blind, placebo-controlled, single center trial with ambroxol in Parkinson patients with a GBA mutation. BMC Neurol. 2024 May 1;24(1):146. doi: 10.1186/s12883-024-03629-9. ↗
Registry derived research reference

Who can join?

Age range not listed · Ask the team who can join

These are starting points, not the full rules. The research team can tell you whether the study is right for your situation.

Read all the rules for taking part

Sex eligibility reported by registry: Not reported

Diagnosis of Parkinson's Disease according to Movement Disorders Society (MDS) criteria GBA1-mutation Disease duration of PD < 10 years at time of inclusion Able to write written informed consent, understanding study protocol and perform protocol related actions Willingness and ability to self-administer oral ambroxol or placebo medication The refusal to be informed about an unforeseen clinical finding Use of an implanted Deep Brain Stimulation (DBS) system History of known sensitivity to the study medication Pregnant or breastfeeding women MRI incompatible implants in the body Any clinically significant or unstable medical or surgical condition that in the opinion of the principal investigator may put the participant at risk when participating in the study or may influence the results of the study or affect the participant’s ability to take part in the study, as determined by medical history, physical examinations, electrocardiogram (ECG), or laboratory tests.
Full study name & original research details

Official study title

GREAT; GRoningen Early-PD Ambroxol Treatment Trial

Original description

To investigate the disease modifying properties of ambroxol in PD patients with a GBA1-mutation

Conditions reported: Parkinson's disease

Registry records for this study

Records are joined using registration identifiers. Titles alone do not establish that two studies are the same.

Study type
Interventional
Interventions
AMBROXOL , Microcrystalline cellulose
Phases
Therapeutic exploratory (Phase II)
Sponsor
Universitair Medisch Centrum Groningen
Start date reported by registry
2023-01-02 (estimated)

Registry updated: 2024-09-23 · Status last verified by the registry submitter: Not reported

Registry records retrieved 2026-10-13 (UTC). Individual records may have older updates. Recruitment and eligibility must be confirmed with the study team.

Contact the research team

Public study contacts supplied to the registry. Ask whether recruitment is still open and what participation involves.

T. van Laar · 0031503612401 · t.van.laar@umcg.nl

Study locations

Site status can differ from overall study status. “Status not reported” means local availability needs confirmation. Remote participation and travel arrangements must be checked with the team.

University Medical Center Groningen

Groningen, Netherlands

Recruiting

Olav Siemeling · 0031 (0)50 3615639 · o.siemeling@umcg.nl

Teus van Laar, Prof. dr.

Facility not reported

Netherlands

Status not reported

Universitair Medisch Centrum Groningen

Groningen, Netherlands

Recruiting

The original descriptions and participation rules come from the registry. Participation is voluntary and does not guarantee benefit.